Clinical trials: Bacterial Diseases
Latent Tuberculosis, End Stage Renal Disease
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.
- Conditions
- Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney, Renal Transplant Candidate for Left Kidney
- Trial name
- NCT05411744
- Testing
- 1 month Rifapentine, Isoniazid and Vitamin B6
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rutgers, The State University of New Jersey
Monoclonal Gammopathy, Tuberculosis
Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis
The purpose of this study is to determine whether the monoclonal protein in patients with tuberculosis and monoclonal gammopathy has anti-tuberculous activity, and whether genes coding their monoclonal proteins show…
- Trial name
- NCT00173264
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Pneumococcal Disease
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
The purpose of this study is to learn about the safety of 20-valent Pneumococcal Conjugate Vaccine (PREVENAR 20) under actual clinical practice in Japan.
- Trial name
- NCT06622109
- Testing
- 20-valent Pneumococcal Conjugate Vaccine
- Where
- Japan
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Tetanus, Poliomyelitis
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
This study is designed to evaluate the safety and immunogenicity of new formulations of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744) when administered as a primary vaccination course to healthy infants at 2, 3 and 4…
- Conditions
- Tetanus, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b
- Trial name
- NCT01248884
- Testing
- Infanrix hexa™, Prevenar 13®, GSK217744
- Where
- 16 sites in Dominican Republic, Finland
- Volunteers
- 721 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis, Post Tuberculosis
LIFE-TB ; Long-Term Impacts on Lung Health and Life After Tuberculosis in Korea
This is a prospective, multicenter observational cohort study aimed at establishing a nationwide post-TB lung disease registry in Korea.
- Trial name
- NCT06946784
- Where
- South Korea
- Volunteers
- 360 people
- Sponsor
- Yonsei University
Melioidosis Pneumonia
Causes of Pneumonia in Yangon
This study will evaluate a new point of care diagnostic test for the diagnosis of melioidosis pneumonia in patients attending outpatient clinics in Yangon, Myanmar
- Trial name
- NCT03578133
- Testing
- InBios® Active Melioidosis DetectTM-Lateral Flow Assay
- Where
- Burma
- Volunteers
- 300 people
- Sponsor
- Myanmar Oxford Clinical Research Unit
Tuberculosis
Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents
Mycobacterium tuberculosis (M. tb) is a pathogen with worldwide distribution which infects humans causing tuberculosis (TB), a transmissible disease resulting in very high mortality and morbidity; development of an effective…
- Trial name
- TB036 (NCT02178748)
- Testing
- MVA85A
- Where
- Uganda
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Leukemia, Leukemia, Myeloid
Breath Analysis for the Detection of Invasive Fungal Infections
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Lymphoblastic, Neutropenia
- Trial name
- REDEFINE (NCT06537726)
- Testing
- Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
- Where
- Switzerland
- Volunteers
- 130 people
- Sponsor
- University of Zurich
Sepsis, Infection, Bacterial
Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy
This prospective clinical study will investigate if antibiotic concentrations in patients with severe infections can be monitored by the UV-VIS spectroscopy.
- Trial name
- NCT04282785
- Testing
- Concentration monitoring of antibiotics in plasma
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Uppsala University
Syphilis
Investigational Study to Evaluate the DPP® Syphilis Screen & Confirm Antibody Point-of-care Test (POCT) to Diagnose Infectious Syphilis
The goal of this observational study is to evaluate the sensitivity, specificity, and utility of the DPP® Syphilis Screen \& Confirm antibody point-of-care test (POCT) to diagnose infectious syphilis in participants attending the…
- Trial name
- NCT06927843
- Testing
- point of care test
- Where
- Canada
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Bacterial Vaginosis
Flourish HEC to Prevent Recurrence of BV
In a population of women with heightened vulvovaginal sensitivity and recurrent bacterial vaginosis (BV), the use of the Flourish HEC Vaginal Care System is being tested for prevention of BV recurrence over six months of use.
- Trial name
- NCT05386147
- Testing
- Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vaginal Biome Science
Group B Streptococcal Infection
Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV
A randomised, placebo-controlled, double-blind study to evaluate the safety, tolerability and immunogenicity of the GBS-NN/NN2 (Recombinant protein vaccine against Group B Streptococcus) vaccine in women living with HIV and women…
- Trial name
- NCT04596878
- Testing
- GBS-NN/NN2
- Where
- 3 sites in South Africa, Uganda
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Bacterial Disease Carrier, Cystic Fibrosis
A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa
This is a phase 1b/2 study of a single dose of intravenous (IV) bacteriophage in males and non-pregnant females, at least 18 years old, diagnosed with Cystic Fibrosis (CF).
- Trial name
- NCT05453578
- Testing
- WRAIR-PAM-CF1
- Where
- 19 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumococcal Infectious Disease
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday).
- Trial name
- NCT06617715
- Testing
- Sinovac PCV13, Prevnar®
- Where
- China
- Volunteers
- 3,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Tuberculosis
The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)
3-way cross-over single dose design evaluating bioavailability of 2 rifampicin-containing FDCs vs a single drug comparator in healthy volunteers
- Trial name
- BIO3FDC (NCT02953847)
- Testing
- Rimactane, Rifafour e-275, Rimactazid 150/75
- Where
- South Africa
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
Conjunctival Bacterial Flora
Effectiveness of Topical 0.5% Levofloxacin to Reduce the Conjunctival Bacterial Flora Before Intraocular Surgery
The purpose of this study is to determine whether additional topical application of 0.5% levofloxacin is more effective in reducing the load of the conjunctival bacterial flora in patients scheduled for intraocular surgery than…
- Trial name
- NCT00491049
- Testing
- 0.5% levofloxacin eye drops
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Botulism
Botulism Outbreak in Thailand (Episode II)
A second botulism outbreak in Northern Thailand was reported in 2006. 192 people were exposed to raw meat and the gut of deer, 83 suffered from diarrhea. Of these 5 developed respiratory failure, 1 impending respiratory failure.
- Trial name
- NCT00348426
- Testing
- Botulinum AntiToxin, neuro-electrophysiologic study, repetitive nerve stimulation, : Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Pneumococcal Pneumonia
PCV10 Reactogenicity and Immunogenicity Study - Malindi
The World Health Organization has recommended that developing countries should incorporate pneumococcal conjugate vaccine (PCV) into their routine immunization schedules.
- Trial name
- PRISM (NCT01028326)
- Testing
- PCV10 and DTaP, hepatitis A vaccine, DTaP, PCV10
- Where
- Kenya
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Cystic Fibrosis, Pseudomonas Aeruginosa
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients…
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa, Pulmonary Exacerbation
- Trial name
- NCT00333385
- Testing
- ceftazidime
- Where
- 15 sites in France
- Volunteers
- 120 people
- Sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Pneumonia, Ventilator Associated Pneumonia
Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa
The objectives of this open study are to assess the safety, tolerability, pharmacokinetics and clinical outcome of patients who have HAP caused by Pseudomonas aeruginosa serotype O11 after three separate administrations of…
- Trial name
- NCT00851435
- Testing
- KBPA-101
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- Kenta Biotech Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.